DKSH, the leading Market Expansion Services provider with a focus on Asia, has established a partnership with Minsheng Pharma, a well-established healthcare company from China, to market and distribute the company’s Baini eye drops (Bendazac Lysine) in China
SHANGHAI, Nov. 18, 2014 /PRNewswire/ — DKSH Business Unit Healthcare, the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia, will provide marketing and sales, distribution and logistics and after-sales services for the product to pharmacies and hospitals in China.
Baini is one of Minsheng Pharma’s flagship products. The product is aimed at preventing cataract, a clouding of the lens inside the eye which leads to a decrease in vision that is common among elderly.
"We are seeing great potential in the medicine market for elderly. The growth rate of cataract prevention medicine has been continuously high in the past few years. It is important for us to work with the leading Market Expansion Services provider to market and distribute Baini that has tremendous potential for business success. Through DKSH’s healthcare capabilities in China, we will be able to make Baini available to more patients across the country, and we will have a stronger presence and market share in the over-the-counter market," said Yang Jun, General Manager, Hangzhou Minsheng Pharmaceutical Co., Ltd. "We are further expanding our ophthalmology product line through R&D and acquisitions and expect to add more products to our cooperation with DKSH in the near future."
"The new partnership with Minsheng Pharma is testament to our capabilities and strength in the over-the-counter and medical channel, which are key pillars in our business model. We are proud to be working with Minsheng Pharma to provide our commercial services for initially their ophthalmology product. Minsheng is a very prominent company and is active in many therapeutic areas. We expect to expand our cooperation step by step," said John Woo, Head of Country Management Team for DKSH China.
The new agreement will further strengthen DKSH’s market position in China while contributing incrementally to the Group’s overall profitability over time.
DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets.
Publicly listed on the SIX Swiss Exchange since March 2012, DKSH is a global company headquartered in Zurich. With 735 business locations in 35 countries – 710 of them in Asia – and 27,200 specialized staff, DKSH generated net sales of CHF 9.6 billion in 2013.
DKSH Business Unit Healthcare is the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia. Custom-made offerings comprise registration and market entry studies as well as importation, customs clearance, marketing and sales to physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include ethical pharmaceuticals, consumer health, over-the-counter (OTC), as well as medical devices. With 150 business locations in 14 countries and around 9,050 specialized staff, Business Unit Healthcare serves over 160,000 customers and generated net sales of around CHF 4.3 billion in 2013.
About Minsheng Pharma
Hangzhou Minsheng Pharmaceutical Group Co., Ltd., founded on the basis of Hangzhou Minsheng Pharmaceutical Group Company (formerly Hangzhou Minsheng Pharmaceutical Factory), is a large key enterprise of national pharmaceutical industry and one of the firstly approved "China’s Time – honored Brand" enterprises.
Established on 1926, it is one of the earliest four chemical pharmaceutical factories in China. As the earliest pharmaceutical factory, the company has been specializing in the pharmaceutical industry since 1926, witnessed the entire history of western medicine in China.